- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05270148
High-intensity Interval Training Versus Fatmax Training in Diabetic Type 2 (Lipidox)
October 31, 2022 updated by: University of Cadiz
The project investigates the effects of two exercise protocols at different intensities, high-intensity interval training and constant load at Fatmax, for 12 weeks in maximal fat oxidation, hormonal regulation of appetite, and insulin sensitivity in persons with obesity and type 2 diabetes mellitus.
The participants will be of both sexes with ages between 40 and 55 years, belonging to the Province of Cádiz.
Sixty volunteers will be randomly allocated into three groups: High-Intensity Interval TRaining (HIIT), Fatmax, and control groups.
The assessments will be at the previous exercise intervention, posterior the exercise intervention, and 12 weeks after the last intervention.
The outcome variables will include body composition, oral glucose tolerance test, appetite, plasma glucose, lipids in plasma, hormones, and adipokines.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
60
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Edgardo Opazo, MSc
- Phone Number: +34677885759
- Email: ed.opazodiaz@alum.uca.es
Study Contact Backup
- Name: Juan Corral
Study Locations
-
-
Cadiz
-
Puerto Real, Cadiz, Spain, 11510
- Recruiting
- Science of Education Faculty
-
Contact:
- Jesus Ponce, PhD
- Phone Number: +34 956 016209
- Email: jesusgustavo.ponce@uca.es
-
Sub-Investigator:
- Edgardo Opazo, MSc
-
Principal Investigator:
- Jesus Ponce, PhD
-
Principal Investigator:
- Cristina Casals, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Non-smoking
- Non-alcoholic (<3 standard drinks per day)•Body mass index >25 kg/m maintaining the habitual dietary patterns without a body mass reduction higher than 2% during the last 6 months
- Not being insulin dependent
- Absence of injury, disease or disability or other known medical condition which could affect the ability to successfully participate in physical exercise tests
- Absence of cardiovascular disease (angina, peripheral or cerebro-vascular disease, etc.).
- Absence of neurologic and psychiatric diseases.
- Absence of respiratory diseases (pulmonary hypertension, chronic obstructive pulmonary disease, etc.).
- Absence of other metabolic diseases (hyper/hypoparathyroidism, hyper/hypothyroidism, Cushing's disease, Type 1 diabetes, etc.)
- Absence of active inflammatory bowel disease
- Absence of kidney disease
- Absence of tumors
- Absence of coagulation dysfunction
- Not under treatment with medications k known to affect glucose metabolism, recent steroid treatment (within 6 months), or hormone replacement therapy
- Be able to understand communication in Spanish or English.
Exclusion Criteria:
- They do not attend more than 2 or 4 consecutive sessions of nutritional counseling or physical training respectively.
- Missing more than 4 or 6 sessions in total of nutritional counseling or physical training respectively.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: HIIT Group
Participants are enrolled in a high-intensity interval training exercise program
|
12 weeks training High-Intensity Interval Training consists of 3 sessions per week in a cycle ergometer, with 1-2days off between sessions, under the supervision of a personal trainer.
HIIT program will consist of 3-5 series of 1 min duration at 90-130% of its maximum power (determined in the first training session), with 90 seconds of rest between sets (estimated total time of the session: 10 minutes).Depending on the number of training session, the loadand the series will increase up to 40% more than the maximum load.
|
|
Active Comparator: FatMax Group
Participants who are enrolled in a moderate-intensity continuous training exercise program
|
12 weeks training Fatmax consist in 3 sessions per week in a cycle ergometer, with 1-2days off between sessions, under the supervision of a personal trainer.
MICTprogram will consist of sessions of approximately ˜45min of moderate aerobic exercise (at the intensity at which the maximal fat oxidation was achieved in the laboratory test) in cycle ergometer.
|
|
No Intervention: Control
Participants who do not receive an exercise program.
They will be instructed to maintain their normal life habits with respect to physical activity and diet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximal fat oxidation (MFO)
Time Frame: 12 weeks
|
Maximal fat oxidation test (MFO) to determine the maximal fat oxidation during exercise (MFO), a gradual test on cycloergometer (Lode Excalibur, Netherlands) will be performed.
The test will begin with a load of 15 Watts, increasing 15Watts every 3 minutes until the respiratory quotient reaches a stable value of 1 or higher.
Throughout the test a cadence of 80 r.p.m. will be maintained.
Calculation in the base of expired gases will be made for the estimation of grams per minute of fat oxidation.
|
12 weeks
|
|
Cardiorespiratory fitness
Time Frame: 12 weeks
|
The maximal oxygen consumption (VO2max) during exercise in liters per minute by a gradual test on a cycle ergometer (Lode Excalibur, Netherlands) will be performed.
The gas exchange will be measured by Jaeger MasterScreen CPX® (CareFusion, San Diego, USA)The test will be continuing the MFO from the load when the respiratory quotient reaches a stable value of 1 or higher.
Once this point is reached, 15 Watts increments will occur every minute until exhaustion is reached, until achieving the VO2max.
Throughout the test a cadence of 80 r.p.m. will be maintained.
Heart rate will be recorded in beats per minute.
|
12 weeks
|
|
Blood samples
Time Frame: 12 weeks
|
Glucose and insulin concentrations will be determined using ELISA technique and will be combined to report the Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) insulin sensitivity index will be calculated
|
12 weeks
|
|
Appetite assessment
Time Frame: 12 weeks
|
Since appetite feeling modulate nutritional behaviour, the evaluation of appetite among the intervention groups can improve the quality of the study from a comprehensive perspective.
After a period of 8-10 hours of fasting, an analog visual scale (AVS) will be completed in order to ensure the appetite felt by the participant in the morning.
The AVS runs from 1 to 10, being the lowest value no appetite at all, and the maximum full appetite.
|
12 weeks
|
|
Body composition: Fatmass and Fat-free mass.
Time Frame: 12 weeks
|
Body composition will be estimated using a multifrequency bioimpedance of 8 electrodes previously validated (TANITAMC780MA).
The calculation of impedance can estimate the fat mass and fat-free mass in kilograms.
The patients will wear light clothing and will assume a posture in accordance with the manufacturers' instructions.
Other previous considerations will be followed 24 hours before the measure: (i) to refrain from vigorous exercise, (ii) to take alcoholic drinks, (iii) to take energy drinks, and (iv) to be in a fasting state for at least 8 hours.
Hydration status will be controlled through a urine color scale from clear to dark during the 7 days before assessment for adjusting variables.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Accelerometry
Time Frame: 12 weeks
|
Physical activity assessment will be carried out through accelerometers (direct method) at the wrist during 7consecutive days.
The data generated by the accelerometers will be analysed by using ActiLife 6.6.2 software (ActiGraph, Florida; USA), using Freedson (1998) cut-points for adults and Choi's validation.
The software calculates in the base the movements of the accelerometer's time of light, moderate, and vigorous physical activity in minutes.
|
12 weeks
|
|
Assessed changes from physical activity
Time Frame: 12 weeks
|
Physical activity assessment will be estimated by the participant's self-reported International Physical Activity Questionnaire Short Version (IPAQ-SF) previously validated in Spain.
The IPAQ-SF estimates the sedentary time, moderate and vigorous activity time in minutes per week.
The questionnaire made a classification in high physical activity level (>3000 of the metabolic equivalent of task (MET) minute per week in moderate or >1500 MET min/week in vigorous activity), moderate physical activity level (>600 MET min/week of moderate or vigorous activity), and low activity level (<600 MET min/week of moderate or vigorous activity)
|
12 weeks
|
|
Blood pressure
Time Frame: 12 weeks
|
Systolic and diastolic blood pressures will be recorded three times by using the validated bloodpressure monitoring device with the participant seated, back supported in chair and feet flat on floor without legscrossed, after they rested 5 minutes.
The guidelines of the Hypertension and Cardiology European Societies and the Spanish one will be used to classify blood pressure stages of participants.
|
12 weeks
|
|
Self-reported quality of life
Time Frame: 12 weeks
|
Self-reported quality of life will be registered by applying the Short Form 36-health survey (SF-36) questionnaire previously validated in Spain.
The SF-36 is a generic measure of quality of life and has been evaluated for a wide variety of medical conditions, including diabetes.
The SF-36 includes 36 questions that evaluate 8 subscales, scores for each scale range from 0 to 100, with higher scores indicating a higher level of function or wellbeing.
The physical component summary is derived from the 4 subscales of physical functioning, role physical, bodily pain, and general health; while the mental component summary is derived from the subscales of vitality, social functioning, role emotional, and mental health.
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Jesús Ponce, PhD, University of Cadiz
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 10, 2022
Primary Completion (Anticipated)
September 1, 2023
Study Completion (Anticipated)
August 31, 2024
Study Registration Dates
First Submitted
December 17, 2021
First Submitted That Met QC Criteria
February 25, 2022
First Posted (Actual)
March 8, 2022
Study Record Updates
Last Update Posted (Actual)
November 3, 2022
Last Update Submitted That Met QC Criteria
October 31, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Lipidox
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.